Skip to main content

Barclays Keeps Their Buy Rating on Scholar Rock Holding (SRRK)

Tipranks - Tipranks - Thu Mar 5, 3:50AM CST

Barclays analyst Etzer Darout maintained a Buy rating on Scholar Rock Holding today and set a price target of $53.00.

Claim 70% Off TipRanks Premium

According to TipRanks, Darout is a 5-star analyst with an average return of 26.1% and a 55.72% success rate. Darout covers the Healthcare sector, focusing on stocks such as Incyte, Syndax Pharmaceuticals, and AnaptysBio.

Scholar Rock Holding has an analyst consensus of Strong Buy, with a price target consensus of $53.78.

See the top stocks recommended by analysts >>

Based on Scholar Rock Holding’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $102.22 million. In comparison, last year the company had a GAAP net loss of $64.48 million

Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRRK in relation to earlier this year. Last month, Invus Global Management, LLC, a Major Shareholder at SRRK bought 1,575,008.00 shares for a total of $11,576,308.80.

Read More on SRRK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).